SciVision Biotech board approves repurchase of 5 million treasury shares for employee transfer

SciVision Biotech Inc. announced that its board of directors resolved on May 14, 2026, to repurchase common shares for the purpose of transferring them to employees. The planned repurchase period runs from May 15, 2026, to July 13, 2026. The company expects to repurchase 5,000,000 shares, representing 6.68% of its total issued shares. The maximum repurchase amount is NT$1,209,727,751, with a repurchase price range of NT$38.10 to NT$90.30 per share. If the company’s share price falls below the lower end of the price range, the company will continue the repurchase. The shares will be bought back from the centralized securities exchange market. As of the filing date, the company held no treasury shares. In the previous five years, the company had planned to repurchase 5,000,000 shares between January 28, 2026, and March 27, 2026, but actually repurchased zero shares, resulting in a 0% execution rate. The company stated that the previous repurchase was not completed in order to protect shareholder interests while taking market mechanisms into account. The board also approved the company’s fourth set of rules for transferring repurchased shares to employees. Under these rules, the repurchased shares may be transferred to eligible employees in one or multiple tranches within five years from the start date of the repurchase. Any shares not transferred by the deadline will be deemed unissued shares and cancelled through capital reduction registration in accordance with law. Eligible employees include company employees who have been employed for at least three months before the subscription record date, employees with special contributions approved by the board, and employees of domestic or overseas subsidiaries in which the company directly or indirectly holds more than 50% ownership. The number of shares available for employee subscription will be determined based on job grade, years of service, performance, special contributions and other factors, subject to board approval. Transfers to managerial officers must first be approved by the remuneration committee, while transfers to non-managerial employees must first be approved by the audit committee. The transfer price will generally be the average actual repurchase price. If the number of the company’s issued common shares increases before the transfer, the transfer price will be adjusted according to the increase ratio. The board stated that the total number of shares to be repurchased represents 6.68% of the company’s issued shares, and the maximum amount required for the repurchase represents 31.64% of current assets. After considering the company’s financial condition, the board concluded that the repurchase will not affect the maintenance of the company’s capital. The statement was approved at the same board meeting, with all nine attending directors agreeing to its contents. According to the assessment opinion of President Securities, the decision-making process for SciVision Biotech’s repurchase price range is lawful, the price range is reasonable, and the future execution of the repurchase is not expected to have a material adverse impact on the company’s financial condition or involve any material irregularities.